# T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

> **NCT01853748** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 512 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Paclitaxel
- **DRUG:** Trastuzumab emtansine

## Key facts

- **NCT ID:** NCT01853748
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2019-08-26
- **Final completion:** 2022-06-15
- **Target enrollment:** 512 (ACTUAL)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01853748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01853748, "T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01853748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*